Evidence map›Paper›PMID 33028293›Full record

Trial reportBMC pulmonary medicine2020

Impact of reducing the duration of antibiotic treatment on the long-term prognosis of community acquired pneumonia.

Ane Uranga, Amaia Artaraz, Amaia Bilbao, Jose María Quintana, Ignacio Arriaga, Maider Intxausti, Jose Luis Lobo, Julia Amaranta García, Jesus Camino, Pedro Pablo España

Erratum issuedOpen access · goldAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC pulmonary medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Establishment of anmSystems · 2026
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Ane UrangaDepartment of Pneumology, Osakidetza, Universitary Hospital of Galdakao-Usansolo, Barrio Labeaga s/n, 48960, Galdakao, Bizkaia, Spain. ane.urangaecheverria@osakidetza.eus.
Amaia ArtarazDepartment of Pneumology, Osakidetza, Universitary Hospital of Galdakao-Usansolo, Barrio Labeaga s/n, 48960, Galdakao, Bizkaia, Spain.
Amaia BilbaoResearch Unit, Osakidetza, Universitary Hospital of Basurto, Bilbao, Bizkaia, Spain.
Jose María QuintanaHealth Services Research on Chronic Patients Network (REDISSEC), Galdakao, Bizkaia, Spain.
Ignacio ArriagaDepartment of Pneumology, Osakidetza, Universitary Hospital of Basurto, Bilbao, Bizkaia, Spain.
Maider IntxaustiDepartment of Pneumology, Osakidetza, Universitary Hospital of Basurto, Bilbao, Bizkaia, Spain.
Jose Luis LoboDepartment of Pneumology, Osakidetza, Universitary Hospital of Alava, Vitoria, Alava, Spain.
Julia Amaranta GarcíaDepartment of Pneumology, Osakidetza, Universitary Hospital of Alava, Vitoria, Alava, Spain.
Jesus CaminoDepartment of Pneumology, Osakidetza, Hospital of San Eloy, Barakaldo, Bizkaia, Spain.
Pedro Pablo EspañaDepartment of Pneumology, Osakidetza, Universitary Hospital of Galdakao-Usansolo, Barrio Labeaga s/n, 48960, Galdakao, Bizkaia, Spain.
Hospital de Galdakao · ESHospital de Basurto · ESOsakidetza · ESHospital de Cruces · ESHospital Universitario Araba · ES

Funding

BBK-BIOCRUCES POST-MIR COURSE 2018/007FELLOWS SCHOLARSHIP SPANISH PULMONOLOGY AND THORACIC SURGERY SOCIETY 011/2013HEALTH DEPARTMENT OF BASQUE COUNTRY GOVERNMENT 2010111095PHARMACY DEPARTMENT OF SPANISH GOVERNMENT EC10-157Sociedad Española de Neumología y Cirugía Torácica 101/2016
6 · The paper itself

Abstract

backgroundThe optimal duration of antibiotic treatment for community-acquired pneumonia (CAP) is not well established. The aim of this study was to assess the impact of reducing the duration of antibiotic treatment on long-term prognosis in patients hospitalized with CAP.

methodsThis was a multicenter study assessing complications developed during 1 year of patients previously hospitalized with CAP who had been included in a randomized clinical trial concerning the duration of antibiotic treatment. Mortality at 90 days, at 180 days and at 1 year was analyzed, as well as new admissions and cardiovascular complications. A subanalysis was carried out in one of the hospitals by measuring C-reactive protein (CRP), procalcitonin (PCT) and proadrenomedullin (proADM) at admission, at day 5 and at day 30.

resultsA total of 312 patients were included, 150 in the control group and 162 in the intervention group. Ninety day, 180 day and 1-year mortality in the per-protocol analysis were 8 (2.57%), 10 (3.22%) and 14 (4.50%), respectively. There were no significant differences between both groups in terms of 1-year mortality (p = 0.94), new admissions (p = 0.84) or cardiovascular events (p = 0.33). No differences were observed between biomarker level differences from day 5 to day 30 (CRP p = 0.29; PCT p = 0.44; proADM p = 0.52).

conclusionsReducing antibiotic treatment in hospitalized patients with CAP based on clinical stability criteria is safe, without leading to a greater number of long-term complications.

Indexed as

HospitalizationAdrenomedullinAgedAged, 80 and overAnti-Bacterial AgentsBiomarkersCommunity-Acquired InfectionsC-Reactive ProteinDrug Administration ScheduleFemaleHumansLogistic ModelsMaleMiddle AgedPneumonia, BacterialProcalcitoninAdrenomedullinAnti-Bacterial AgentsBiomarkersC-Reactive ProteinproadrenomedullinProcalcitoninProtein PrecursorsAntibioticComplicationsDurationPneumoniaPrognosis

Identifiers

PMID33028293
PMCPMC7538840
OpenAlexW3092500257

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.